Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANSOLYSEN vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Severe hypertension,Hypertensive crisis
Hypertension
Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 24-48 hours in renal impairment, necessitating dose adjustment.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Hepatic metabolism; excreted primarily unchanged in urine.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal excretion predominates (approximately 70-80% as unchanged drug via glomerular filtration; remainder as metabolites). Biliary/fecal elimination accounts for <10%.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Approximately 30-40% bound to serum albumin; binding is reversible and concentration-independent.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Vd is 0.5-1.0 L/kg indicating extensive tissue distribution (primarily in highly perfused organs), with little accumulation in fat.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral bioavailability is low (10-25%) due to significant first-pass metabolism; subcutaneous bioavailability >90%; intramuscular near 90%; intravenous 100%.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated in severe renal impairment. For GFR 10-50 m L/min: reduce dose by 50% and increase dosing interval. For GFR <10 m L/min: avoid use.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
No specific guidelines; use with caution in severe hepatic impairment due to potential for increased toxicity.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not established; safety and efficacy in children have not been determined.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Use with caution; start at lower end of dosing range due to increased sensitivity and risk of hypotension and falls.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None specified in standard references.
None
Severe hypotension,Paralytic ileus,Bladder atony,Pupillary dilatation and photophobia,Loss of accommodation,Syncope and precipitating angina,Interstitial pulmonary edema and fibrosis
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to pentolinium,Uncooperative patients,Coronary insufficiency,Recent myocardial infarction,Severe renal impairment,Pyloric stenosis,Glaucoma,Bladder neck obstruction,Prostatic hypertrophy
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) as ganglionic blockers may potentiate pressor responses. Limit salt intake to manage blood pressure. Grapefruit juice may alter drug metabolism? No known significant interaction; however, general caution with high-tyramine foods is advised.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Potential for teratogenic effects based on animal studies; human data limited. Second and third trimesters: Risk of fetal bradycardia, hypothermia, and respiratory depression due to ganglionic blockade. May cause neonatal hypotension if used near term.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Excretion in human milk unknown; M/P ratio not available. Due to potential for adverse effects in nursing infants (e.g., hypotension, gastrointestinal disturbances), caution advised; consider alternative therapy.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No specific dosing guidelines; monitor maternal response carefully. Increased volume of distribution may require higher doses, but increased sensitivity may necessitate dose reduction. Use lowest effective dose.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
ANSOLYSEN (mecamylamine) is a secondary amine and a ganglionic blocker used in severe hypertension. Due to its narrow therapeutic index and risk of paralytic ileus, it is rarely used today. Monitor for orthostatic hypotension, urinary retention, and constipation. Avoid in patients with pyloric stenosis, recent myocardial infarction, or glaucoma. Use with caution in renal impairment as drug is renally excreted.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not double doses if missed.,Rise slowly from lying or sitting to prevent dizziness.,Avoid alcohol and hot baths/saunas as they may worsen hypotension.,Report severe constipation, difficulty urinating, or blurred vision immediately.,Do not discontinue abruptly; taper under medical supervision.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANSOLYSEN vs ALDORIL D30, answered by our medical review team.
ANSOLYSEN is a Antihypertensive that works by Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANSOLYSEN and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANSOLYSEN is: Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANSOLYSEN and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANSOLYSEN is classified as Category C. First trimester: Potential for teratogenic effects based on animal studies; human data limited. Second and third trimesters: Risk of fetal bradycardia, hypothermia, and respiratory. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.